IMNN Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Imunon, Inc.'s net margin of 16.99%. Imunon, Inc.'s return on equity of -365% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Imunon, Inc. has a consensus price target of $21.50, signalling upside risk potential of 561.54%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that Imunon, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Imunon, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Imunon, Inc. has a beta of 2.057, which suggesting that the stock is 105.729% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.

Imunon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Imunon, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Imunon, Inc.'s net income of -$3.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Imunon, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon, Inc. is 16.43x versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Imunon, Inc.'s net margin of -5.2%. Imunon, Inc.'s return on equity of -365% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.

Imunon, Inc. has a consensus price target of $21.50, signalling upside risk potential of 561.54%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.17 which suggests that it could grow by 42.84%. Given that Imunon, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Imunon, Inc. is more attractive than BioMarin Pharmaceutical, Inc..

Imunon, Inc. has a beta of 2.057, which suggesting that the stock is 105.729% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.229%.

Imunon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Imunon, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Imunon, Inc.'s net income of -$3.4M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Imunon, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon, Inc. is 16.43x versus 3.70x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics, Inc. has a net margin of -- compared to Imunon, Inc.'s net margin of 11.83%. Imunon, Inc.'s return on equity of -365% beat Corcept Therapeutics, Inc.'s return on equity of 14.97%.

Imunon, Inc. has a consensus price target of $21.50, signalling upside risk potential of 561.54%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $65.40 which suggests that it could grow by 83.19%. Given that Imunon, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Imunon, Inc. is more attractive than Corcept Therapeutics, Inc..

Imunon, Inc. has a beta of 2.057, which suggesting that the stock is 105.729% more volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.236%.

Imunon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Imunon, Inc. quarterly revenues are --, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $202.1M. Imunon, Inc.'s net income of -$3.4M is lower than Corcept Therapeutics, Inc.'s net income of $23.9M. Notably, Imunon, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 43.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon, Inc. is 16.43x versus 5.62x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -- compared to Imunon, Inc.'s net margin of --. Imunon, Inc.'s return on equity of -365% beat Savara, Inc.'s return on equity of -78.83%.

Imunon, Inc. has a consensus price target of $21.50, signalling upside risk potential of 561.54%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.61%. Given that Imunon, Inc. has higher upside potential than Savara, Inc., analysts believe Imunon, Inc. is more attractive than Savara, Inc..

Imunon, Inc. has a beta of 2.057, which suggesting that the stock is 105.729% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.

Imunon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Imunon, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Imunon, Inc.'s net income of -$3.4M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Imunon, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon, Inc. is 16.43x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.